PharmaTher Holdings Ltd. announced a strategic initiative to expand its PharmaPatch microneedle patch platform into select therapeutic peptides for the U.S. market. The company plans to evaluate delivery feasibility for peptide candidates including BPC-157, GHK-Cu, TB-500 and KPV, as well as potential combinations, using a staged R&D framework aligned with applicable regulatory requirements. PharmaTher also plans to advance the initiative through clinical evaluation, manufacturing and scale-up assessment, and intellectual property filings related to peptide delivery work.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharmather Holdings Ltd. published the original content used to generate this news brief on March 03, 2026, and is solely responsible for the information contained therein.